Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

This early-phase study tests a new cell therapy called PRAME-TCR-NK cells — immune cells engineered to recognize and attack melanoma — in people with advanced or metastatic melanoma that stopped responding to immunotherapy drugs like anti-PD-1 or anti-CTLA-4. **You may be eligible if...** - You are 18 or older with advanced, unresectable, or metastatic melanoma - Your melanoma has stopped responding to at least one immunotherapy regimen - You carry a specific immune marker called HLA-A*02:01 - You are generally well enough to carry out daily activities (ECOG 0–1) - Your life expectancy is at least 3 months - You have received no more than 3 prior lines of anti-PD-1 therapy **You may NOT be eligible if...** - You do not carry the HLA-A*02:01 marker - You have untreated brain metastases - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.